Transcenta Says Regulators Approve Osemitamab Global Phase III Trial
Transcenta says regulators in the U.S., China and South Korea approved a global Phase III trial of osemitamab.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.